[Home ] [Archive]   [ فارسی ]  
:: Main :: About :: Current Issue :: Archive :: Search :: Submit :: Contact ::
Main Menu
Home::
Journal Information::
Articles archive::
For Authors::
For Reviewers::
Registration::
Contact us::
Site Facilities::
Webmail::
::
Search in website

Advanced Search
..
Receive site information
Enter your Email in the following box to receive the site news and information.
..
:: Volume 22, Issue 2 (summer 2012) ::
MEDICAL SCIENCES 2012, 22(2): 157-162 Back to browse issues page
Long-term effects of peg-interferon alfa-2a and ribavirin in hemophilic patients with chronic hepatitis C
Siamak Khaleghi1 , Mahshid Talebi Taher 2, Salma Ahi3
1- Gastroenterologist, Department of Internal Medicine, Tehran University of Medical Sciences, Tehran, Iran
2- Specialist of Infectious Diseases, Antimicrobial Resistance Research Center, Tehran University of Medical Sciences, Tehran, Iran , m-talebitaher@tums.ac.ir
3- Resident of Internal Medicine, Tehran University of Medical Sciences, Tehran, Iran
Abstract:   (16993 Views)
Background: chronic hepatitis C infection is a major health problem in hemophilia patients. There is no enough evidence about the long term outcome and efficacy of treatment in these patients. The aim of this study was to evaluate the clinical, biochemical and virologic outcome of chronic hepatitis C treated with peginterferone alfa2-a and ribavirin in hemophilia patients during a five- year follow up.
Materials and Methods: In a retrospective cohort study, 35 hemophilia patients with chronic HCV infection who were treated by peginterferon and ribavirin were studied. The efficacy of therapy was expressed as sustained virologic response (SVR: undetectable HCVRNA after six month of standard therapy). Association of efficacy of therapy and genotyping were analyzed by chi-square using SPSS ver.15 software. P<0.05 was considered statistically significant.
Results: twenty seven patients (93.1%) achieved SVR, six patients did not respond. Follow up after 3 and 5years of treatment showed the same results. No evidence of virologic, biochemical and clinical relapse were detected. None of the patients were demonstrated hepatitis decompensation or hepatocellular carcinoma.
Conclusion: It seems that sustained virologic response and the absence of clinical, virologic relapse after long term follow up (5 years) means the rescue from the fetal hepatitis infection.
Keywords: Hemophilia, Hepatitis C, Treatment, Peg-interferone alfa2-a, Ribavirin
Full-Text [PDF 129 kb]   (3597 Downloads)    
Semi-pilot: Cohort | Subject: Gastrology
Received: 2012/06/27 | Published: 2012/06/15
Send email to the article author

Add your comments about this article
Your username or Email:

CAPTCHA


XML   Persian Abstract   Print


Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

Khaleghi S, Talebi Taher M, Ahi S. Long-term effects of peg-interferon alfa-2a and ribavirin in hemophilic patients with chronic hepatitis C. MEDICAL SCIENCES 2012; 22 (2) :157-162
URL: http://tmuj.iautmu.ac.ir/article-1-572-en.html


Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Volume 22, Issue 2 (summer 2012) Back to browse issues page
فصلنامه علوم پزشکی دانشگاه آزاد اسلامی واحد پزشکی تهران Medical Science Journal of Islamic Azad Univesity - Tehran Medical Branch
Persian site map - English site map - Created in 0.05 seconds with 37 queries by YEKTAWEB 4645